Woodline Partners LP decreased its stake in shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) by 15.0% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 426,170 shares of the company's stock after selling 75,066 shares during the quarter. Woodline Partners LP owned about 1.05% of Acumen Pharmaceuticals worth $2,003,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ABOS. Fiduciary Group LLC acquired a new position in shares of Acumen Pharmaceuticals during the 1st quarter worth approximately $31,000. California State Teachers Retirement System increased its position in shares of Acumen Pharmaceuticals by 114.9% during the 1st quarter. California State Teachers Retirement System now owns 12,162 shares of the company's stock worth $48,000 after purchasing an additional 6,503 shares during the last quarter. American International Group Inc. lifted its position in shares of Acumen Pharmaceuticals by 163.3% during the 1st quarter. American International Group Inc. now owns 14,047 shares of the company's stock worth $55,000 after buying an additional 8,712 shares during the last quarter. Prelude Capital Management LLC bought a new stake in shares of Acumen Pharmaceuticals during the 1st quarter worth $61,000. Finally, JPMorgan Chase & Co. increased its holdings in Acumen Pharmaceuticals by 149.3% in the 1st quarter. JPMorgan Chase & Co. now owns 18,049 shares of the company's stock worth $71,000 after purchasing an additional 10,809 shares in the last quarter. Institutional investors and hedge funds own 63.33% of the company's stock.

Analyst Ratings Changes

ABOS has been the topic of several recent research reports. Credit Suisse Group cut their price target on Acumen Pharmaceuticals from $17.00 to $16.00 and set an "outperform" rating on the stock in a report on Tuesday, November 15th. BTIG Research raised their target price on Acumen Pharmaceuticals from $15.00 to $22.00 and gave the stock a "buy" rating in a research report on Wednesday, October 5th. Finally, HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Acumen Pharmaceuticals in a research report on Tuesday, August 16th.

Acumen Pharmaceuticals Stock Performance

Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.01. On average, research analysts anticipate that Acumen Pharmaceuticals, Inc. will post -1.01 EPS for the current year.

About Acumen Pharmaceuticals

(Get Rating)

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.

See Also

• Get a free copy of the StockNews.com research report on Acumen Pharmaceuticals (ABOS)
• Why the Cracker Barrel Selloff Looks Overcooked
• Coinbase Global Stock is a Falling Meat Cleaver
• It's Still Too Soon to Shop for Kohl's Stock
• Three Small-Cap Biotech Stocks to Consider Now
• Two Blue Chip Health Companies The Institutions Are Buying

Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.